Skip to content

Effect of VPro5 Therapy on Clear Aligner Therapy

Effect of VPro5 Therapy on Clear Aligner Tracking: a Randomized Clinical Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03240770
Enrollment
60
Registered
2017-08-07
Start date
2017-02-03
Completion date
2017-07-20
Last updated
2017-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malocclusion

Keywords

HFV, HFA, High Frequency Vibration

Brief summary

The investigators hypothesize that brief, daily application of HFA will increase the efficiency of clear aligner treatment by altering PDL metabolism without increasing pain or discomfort. The investigators will divide subjects into 5 groups changing clear aligners at different time intervals with or without HFA application for 5 minutes/day to assess the effect on: time intervals between aligners, cytokine activity, and pain perception.

Interventions

DEVICEVPro5 device

Use of the VPro5 device for 5 minutes a day

OTHERDeviation from Standard Tray Wear Time (14 Days)

Patients reduced Tray Wear Time Interval (14 Days)

Sponsors

Propel Orthodontics, LLC
CollaboratorINDUSTRY
Mani Alikhani
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

1. Subject must be 18 - 45 years of age 2. Subject is willing and able to comply with all study procedures and sign Informed consent/HIPAA forms 3. Subject must have complete adult dentition (excluding third molars) 4. Subjects must have class I malocclusion or mild class II/III malocclusions 5. Subject is at least one month into aligner treatment. 6. Subject has history of and current healthy oral hygiene (PD is\<4mm, GI\<1, and PI=1)

Exclusion criteria

1. Subjects who have received periodontal treatment in the previous 6 months 2. Subjects who are taking medication that could affect the level of inflammation, such as chronic antibiotics, phenytoin, cyclosporin, ant-inflammatory drugs, systemic corticosteroids, or calcium channel blockers. 3. Subjects missing adult teeth (except the 3rd molars) or with severe class II or class III malocclusion. 4. Subjects with skeletal class I but extreme dental malocclusion 5. Severe crowding that require extraction 6. More than 4 mm positive overjet and more than 2 mm negative overjet 7. Extreme deep bite (more than 90%); 8. Severe openbite (more than 2 mm) 9. Pregnant women 10. Subjects do not have any systemic diseases effecting bone metabolism 11. Smoking 12. Vulnerable subjects per IRB definitions 13. Subjects with current caries 14. Subjects that require interproximal reduction or attachments during the study period 15. Subjects who are non-compliant regarding aligner wear or VPro5 recommended daily usage

Design outcomes

Primary

MeasureTime frameDescription
Average Aligner Tracking PercentageThrough study completion, average of 25 daysAverage assessed via measurement of intraoral scan and prediction software

Secondary

MeasureTime frame
Cytokine LevelsThrough study completion, average of 25 days
Pain Perception via Numerical Rating ScaleDay 1 and Day 3 of each aligner

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026